SCHEMBL2331114

SCHEMBL2331114

COc1ccc2nccc(CC(NC(=O)OCc3ccccc3)[C@@H]3CC[C@@H](N)CO3)c2n1

nearest known ligand 0.37

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.35
ITGB3 P05106 1/20 0.35
ITGAV P06756 1/20 0.35
ITGA2B P08514 1/20 0.35
CYP1A2 P05177 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
TSHR P16473 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360575 0.87 KLK7 (0.37) KCNH2TSHR
SCHEMBL3721902 0.86 KCNH2 (0.36) KCNH2
SCHEMBL2360997 0.86 KCNH2 (0.36) KCNH2
SCHEMBL3721907 0.86 KCNH2 (0.36) KCNH2
SCHEMBL3111386 0.86 KCNH2 (0.36) KCNH2
SCHEMBL2361144 0.86 KLK7 (0.38) KCNH2TSHR
SCHEMBL3114694 0.82 KCNH2 (0.42) KCNH2TSHR
SCHEMBL2330494 0.82 KCNH2 (0.40) KCNH2
SCHEMBL2330490 0.82 KCNH2 (0.40) KCNH2
SCHEMBL2330487 0.82 KCNH2 (0.40) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193179-B2 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-06-05 US disclosed
EP-2167494-B1 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-08-17 EP disclosed
US-20100179135-A1 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179135-A1 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES ELANE, AAAS, DNPEP KCNH2 4015/4885ITGB3 1694/4885ITGAV 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.